Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 573-586

  Callahan, Margaret K ^a,b   Wolchok, Jedd D ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Ludwig Center for Cancer Immunotherapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BUDESONIDE; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; EXEMESTANE; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; SUNITINIB; TICILIMUMAB; TRAMETINIB; TUMOR MARKER; VEMURAFENIB; ANTIBODY; BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLITIS; COMPARATIVE STUDY; CONJUNCTIVITIS; DIARRHEA; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; MAXIMUM TOLERATED DOSE; MELANOMA; MYOPATHY; NEPHRITIS; NEUROPATHY; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMATIC REVIEW; THYROIDITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CTLA-4 ANTIGEN; HUMANS; NEOPLASMS;

EID: 84940392222     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.008     Document Type: Review

References (125)

1. H. Gmunder, and W. Lesslauer A 45-kDa human T-cell membrane glycoprotein functions in regulation of cell proliferative responses Eur J Biochem 142 1 1984 153 160
2. J.A. Hansen, P.J. Martin, and R.C. Nowinski Monoclonal antibodies identifying a novel T-Cell antigen and Ia antigens of human lymphocytes Immunogenetics 11 1 1980 429 439
3. D.J. Lenschow, T.L. Walunas, and J.A. Bluestone CD28/B7 system of T cell costimulation Annu Rev Immunol 14 1996 233 258
4. C.E. Rudd, A. Taylor, and H. Schneider CD28 and CTLA-4 coreceptor expression and signal transduction Immunol Rev 229 1 2009 12 26
5. A. Shahinian, K. Pfeffer, K.P. Lee, and et al. Differential T cell costimulatory requirements in CD28-deficient mice Science 261 5121 1993 609 612
6. T.M. Kundig, A. Shahinian, K. Kawai, and et al. Duration of TCR stimulation determines costimulatory requirement of T cells Immunity 5 1 1996 41 52
7. F. Borriello, M.P. Sethna, S.D. Boyd, and et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation Immunity 6 3 1997 303 313
8. P. Waterhouse, J.M. Penninger, E. Timms, and et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 5238 1995 985 988
9. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 5 1995 541 547
10. C.A. Chambers, T.J. Sullivan, and J.P. Allison Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+T cells Immunity 7 6 1997 885 895
11. E. Corse, and J.P. Allison Cutting edge: CTLA-4 on effector T cells inhibits in trans J Immunol 189 3 2012 1123 1127
12. K.S. Peggs, S.A. Quezada, and J.P. Allison Cell intrinsic mechanisms of T-cell inhibition and application to cancer rapy Immunol Rev 224 2008 141 165
13. T. Shiratori, S. Miyatake, H. Ohno, and et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2 Immunity 6 5 1997 583 589
14. E. Chuang, M.L. Alegre, C.S. Duckett, P.J. Noel, M.G. Vander Heiden, and C.B. Thompson Interaction of CTLA-4 with clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression J Immunol 159 1 1997 144 151
15. Y. Zhang, and J.P. Allison Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein Proc Natl Acad Sci U S A 94 17 1997 9273 9278
16. J.G. Egen, and J.P. Allison Cytotoxic T lymphocyte antigen-4 accumulation in immunological synapse is regulated by TCR signal strength Immunity 16 1 2002 23 35
17. T. Pentcheva-Hoang, J.G. Egen, K. Wojnoonski, and J.P. Allison B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to immunological synapse Immunity 21 3 2004 401 413
18. C.C. Stamper, Y. Zhang, J.F. Tobin, and et al. Crystal structure of B7-1/CTLA-4 complex that inhibits human immune responses Nature 410 6828 2001 608 611
19. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on response of T cells to stimulation J Exp Med 182 2 1995 459 465
20. T.L. Walunas, D.J. Lenschow, C.Y. Bakker, and et al. CTLA-4 can function as a negative regulator of T cell activation Immunity 1 5 1994 405 413
21. W. Chen, W. Jin, and S.M. Wahl Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells J Exp Med 88 10 1998 1849 1857
22. P.J. Blair, J.L. Riley, B.L. Levine, and et al. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction J Immunol 160 1 1998 12 15
23. O.S. Qureshi, Y. Zheng, K. Nakamura, and et al. Trans-endocytosis of CD80 and CD86: A molecular basis for cell-extrinsic function of CTLA-4 Science 332 6029 2011 600 603
24. K. Wing, Y. Onishi, P. Prieto-Martin, and et al. CTLA-4 control over Foxp3+regulatory T cell function Science 322 5899 2008 271 275
25. S. Read, V. Malmstrom, and F. Powrie Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation J Exp Med 192 2 2000 295 302
26. K.S. Peggs, S.A. Quezada, C.A. Chambers, A.J. Korman, and J.P. Allison Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to antitumor activity of anti-CTLA-4 antibodies J Exp Med 206 8 2009 1717 1725
27. M.J. Selby, J.J. Engelhardt, M. Quigley, and et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells Cancer immunology research 1 1 2013 32 42
28. T.R. Simpson, F. Li, W. Montalvo-Ortiz, and et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines efficacy of anti-CTLA-4 rapy against melanoma J Exp Med 210 9 2013 1695 1710
29. J.P. Allison, A.A. Hurwitz, and D.R. Leach Manipulation of costimulatory signals to enhance antitumor T-cell responses Curr Opin Immunol 7 5 1995 682 686
30. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 5256 1996 1734 1736
31. E.D. Kwon, A.A. Hurwitz, B.A. Foster, and et al. Manipulation of T cell costimulatory and inhibitory signals for immunorapy of prostate cancer Proc Natl Acad Sci U S A 94 15 1997 8099 8103
32. Y.F. Yang, J.P. Zou, J. Mu, and et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: Effect is manifested only at restricted tumor-bearing stages Cancer Res 57 18 1997 4036 4041
33. P. Shrikant, A. Khoruts, and M.F. Mescher CTLA-4 blockade reverses CD8+T cell tolerance to tumor by a CD4+T cell- and IL-2-dependent mechanism Immunity 11 4 1999 483 493
34. E.M. Sotomayor, I. Borrello, E. Tubb, J.P. Allison, and H.I. Levitsky In vivo blockade of CTLA-4 enhances priming of responsive T cells but fails to prevent induction of tumor antigen-specific tolerance Proc Natl Acad Sci U S A 96 20 1999 11476 11481
35. J.F. Grosso, and M.N. Jure-Kunkel CTLA-4 blockade in tumor models: An overview of preclinical and translational research Cancer Immun 13 2013 5
36. M.A. Curran, M. Kim, W. Montalvo, A. Al-Shamkhani, and J.P. Allison Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production PLoS One 6 4 2011 e19499
37. S.A. Quezada, K.S. Peggs, M.A. Curran, and J.P. Allison CTLA4 blockade and GM-CSF combination immunorapy alters intratumor balance of effector and regulatory T cells J Clin Invest 116 7 2006 1935 1945
38. G.Q. Phan, J.C. Yang, R.M. Sherry, and et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci U S A 100 14 2003 8372 8377
39. A. Ribas, L.H. Camacho, G. Lopez-Berestein, and et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 J Clin Oncol 23 35 2005 8968 8977
40. J.S. Weber, S. O'Day, W. Urba, and et al. Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 36 2008 5950 5956
41. S. Tchekmedyian, J. Glasby, A. Korman, T. Keler, Y. Deo, and T. Davis MDX-010 (human anti-CTLA4): A phase I trial in malignant melanoma Proc Am Soc Clin Oncol 2002 21 abstr 56
42. A. Tarhini, E. Lo, and D.R. Minor Releasing brake on immune system: ipilimumab in melanoma and or tumors Cancer Bior Radiopharmaceut 25 6 2010 601 613
43. A.V. Maker, G.Q. Phan, P. Attia, and et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study Ann Surg Oncol 12 12 2005 1005 1016
44. S.G. Downey, J.A. Klapper, F.O. Smith, and et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin Cancer Res 13 22 Pt 1 2007 6681 6688
45. E.M. Hersh, S.J. O'Day, J. Powderly, and et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemorapy-naive patients with advanced melanoma Invest New Drugs 29 2010 489 498
46. P. Attia, G.Q. Phan, A.V. Maker, and et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 25 2005 6043 6053
47. K. Sanderson, R. Scotland, P. Lee, and et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma J Clin Oncol 23 4 2005 741 750
48. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
49. D. McDermott, J. Haanen, T.T. Chen, P. Lorigan, and S. O'Day Investigators MDX. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) Ann Oncol 24 10 2013 2694 2698
50. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 26 2011 2517 2526
51. J.M. Reuben, B.N. Lee, C. Li, and et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma Cancer 106 11 2006 2437 2444
52. L.H. Camacho, S. Antonia, J. Sosman, and et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma J Clin Oncol 27 7 2009 1075 1081
53. J.M. Kirkwood, P. Lorigan, P. Hersey, and et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma Clin Cancer Res 16 3 2010 1042 1048
54. A. Ribas, A. Hauschild, R. Kefford, and et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemorapy (temozolomide or dacar- bazine) in patients with advanced melanoma [abstract LBA9011] J Clin Oncol 26 Suppl 2008 2009
55. A. Ribas, R. Kefford, M.A. Marshall, and et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemorapy in patients with advanced melanoma J Clin Oncol 31 5 2013 616 622
56. P.A. Prieto, J.C. Yang, R.M. Sherry, and et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma Clin Cancer Res 18 2012 2039 2047
57. M.A. Postow, M.K. Callahan, and J.D. Wolchok antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Clin Cancer Res 18 7 2012 1821 1823
58. J.D. Wolchok, A. Hoos, S. O'Day, and et al. Guidelines for evaluation of immune rapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 23 2009 7412 7420
59. A.M. Hinds, D.S. Ahmad, J.E. Muenster, and et al. Ipilimumab-induced colitis: A rare but serious side effect Endoscopy 46 Suppl 1 2014 E308 E309 UCTN
60. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
61. J. Weber Ipilimumab: Controversies in its development, utility and autoimmune adverse events Cancer Immunol Immunor 58 5 2009 823 830
62. A.M. Di Giacomo, M. Biagioli, and M. Maio emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications Semin Oncol 37 5 2010 499 507
63. P.M. Forde, K. Rock, G. Wilson, and K.J. O'Byrne Ipilimumab-induced Immune-related Renal Failure - A Case Report Anticancer research 32 10 2012 4607 4608
64. M. Maur, C. Tomasello, A. Frassoldati, M.V. Dieci, E. Barbieri, and P. Conte Posterior reversible encephalopathy syndrome during ipilimumab rapy for malignant melanoma J Clin Oncol 30 6 2012 e76 e78
65. S. Andrews, and R. Holden Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunorapy for metastatic melanoma Cancer management and research 4 2012 299 307
66. https://www.hcp.yervoy.com/pages/rems.aspx.
67. K.E. Beck, J.A. Blansfield, K.Q. Tran, and et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol 24 15 2006 2283 2289
68. J. Wolchok How recent advances in immunorapy are changing standard of care for patients with metastatic melanoma Ann Oncol 23 Suppl 8 2012 viii15 viii21
69. C. Pages, J.M. Gornet, G. Monsel, and et al. Ipilimumab-induced acute severe colitis treated by infliximab Melanoma Res 23 3 2013 227 230
70. K.D. Chmiel, D. Suan, C. Liddle, and et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin rapy J Clin Oncol 29 9 2011 e237 e240
71. M. Ryder, M. Callahan, M.A. Postow, J. Wolchok, and J.A. Fagin Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution Endocr Rel Cancer 21 2 2014 371 381
72. J.D. Wolchok, B. Neyns, G. Linette, and et al. Ipilimumab monorapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2 2010 155 164
73. A. Eggermont, V. Chiarion-Sileni, J. Grob, and et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from EORTC 18071 phase III trial J Clin Onco 32 2014 5s (suppl; abstr LBA9008)
74. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 6 2007 1810 1815
75. E. Small, C. Higano, N. Tchekmedyian, and et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer J Clin Oncol 24 Suppl 2006 4609
76. D.G. McNeel, H.A. Smith, J.C. Eickhoff, and et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer Cancer Immunol Immunor 61 7 2012 1137 1147
77. N. Singh, R.A. Madan, and J.L. Gulley Ipilimumab in prostate cancer Exp Opin Biol r 13 2 2013 303 313
78. E.D. Kwon, C.G. Drake, H.I. Scher, and et al. Ipilimumab versus placebo after radiorapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemorapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 7 2014 700 712
79. T.J. Lynch, I.N. Bondarenko, A. Luft, and et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 15s (suppl; abstr 7531)
80. S.M. Ansell, S.A. Hurvitz, P.A. Koenig, and et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma Clin Cancer Res 15 20 2009 6446 6453
81. A. Bashey, B. Medina, S. Corringham, and et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation Blood 113 7 2009 1581 1588
82. J.C. Yang, M. Hughes, U. Kammula, and et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunor 30 8 2007 825 830
83. R.E. Royal, C. Levy, K. Turner, and et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma J Immunor 33 8 2010 828 833
84. R.H. Vonderheide, P.M. LoRusso, M. Khalil, and et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells Clin Cancer Res 16 13 2010 3485 3494
85. M.A. Postow, S.D. Chasalow, J. Yuan, and et al. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma J Clin Oncol 31 2013 (suppl; abstr 9052)
86. J. Delyon, C. Mateus, D. Lefeuvre, and et al. Experience in daily practice with ipilimumab for treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival Ann Oncol 24 6 2013 1697 1703
87. E. Simeone, G. Gentilcore, D. Giannarelli, and et al. Immunological and biological changes during ipilimumab treatment and ir potential correlation with clinical response and survival in patients with advanced melanoma Cancer Immunol Immunor 63 7 2014 675 683
88. J. Yuan, S. Gnjatic, H. Li, and et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit Proc Natl Acad Sci U S A 105 51 2008 20410 20415
89. J. Yuan, M. Adamow, B.A. Ginsberg, and et al. Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Proc Natl Acad Sci U S A 108 2011 16723 16728
90. N. van Rooij, M.M. van Buuren, D. Philips, and et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma J Clin Oncol 31 32 2013 e439 e442
91. A. Snyder, V. Makarov, T. Merghoub, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 23 2014 2189 2199
92. B.C. Carthon, J.D. Wolchok, J. Yuan, and et al. Preoperative CTLA-4 blockade: Tolerability and immune monitoring in setting of a presurgical clinical trial Clin Cancer Res 16 10 2010 2861 2871
93. D. Ng Tang, Y. Shen, J. Sun, and et al. Increased frequency of ICOS+CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 rapy Cancer Immunol Res 1 4 2013 229 234
94. R.R. Ji, S.D. Chasalow, L. Wang, and et al. An immune-active tumor microenvironment favors clinical response to ipilimumab Cancer Immunol Immunor 61 7 2012 1019 1031
95. D. Hannani, M. Vetizou, D. Enot, and et al. Anticancer immunorapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 Cell Res 25 2015 208 224
96. J. Weber, O. Hamid, A. Amin, and et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemorapy regimens in patients with untreated advanced melanoma Cancer Immun 13 2013 7
97. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
98. T.J. Lynch, I. Bondarenko, A. Luft, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 17 2012 2046 2054
99. S.C. Formenti, and S. Demaria Combining radiorapy and cancer immunorapy: A paradigm shift J Natl Cancer Inst 105 4 2013 256 265
100. M.A. Postow, M.K. Callahan, C.A. Barker, and et al. Immunologic correlates of abscopal effect in a patient with melanoma N Engl J Med 366 10 2012 925 931
101. R.J. Sullivan, D.P. Lawrence, J.A. Wargo, K.S. Oh, R.G. Gonzalez, and A. Piris Case records of Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma N Engl J Med 369 2 2013 173 183
102. C.A. Barker, M.A. Postow, S.A. Khan, and et al. Concurrent radiorapy and ipilimumab immunorapy for patients with melanoma Cancer Immunol Res 1 2 2013 92 98
103. E.B. Golden, S. Demaria, P.B. Schiff, A. Chachoua, and S.C. Formenti An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer Cancer Immunol Res 1 6 2013 365 372
104. A.M. Grimaldi, E. Simeone, D. Giannarelli, and et al. Abscopal effects of radiorapy on advanced melanoma patients who progressed after ipilimumab immunorapy Oncoimmunology 3 2014 e28780
105. C.A. Barker, and M.A. Postow Combinations of radiation rapy and immunorapy for melanoma: A review of clinical outcomes Int J Radiat Oncol Biol Phys 88 5 2014 986 997
106. F.S. Hodi, D. Lawrence, C. Lezcano, and et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma Cancer Immunol Res 2 7 2014 632 642
107. S. Hu-Lieskovan, L. Robert, B. Homet Moreno, and A. Ribas Combining targeted rapy with immunorapy in BRAF-mutant melanoma: Promise and challenges J Clin Oncol 32 21 2014 2248 2254
108. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 14 2013 1365 1366
109. I. Puzanov, M.K. Callahan, G.P. Linette, and et al. Phase 1 study of BRAF inhibitor dabrafenib (D) with or without MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) J Clin Oncol 32 2014 5s (suppl; abstr 2511)
110. B.I. Rini, M. Stein, P. Shannon, and et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma Cancer 117 4 2011 758 767
111. A. Watanabe, M. Hara, E. Chosa, and et al. Combination of adoptive cell transfer and antibody injection can eradicate established tumors in mice - an in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb Immunopharmacol Immunotoxicol 32 2 2010 238 245
112. S.N. Linch, and W.L. Redmond Combined OX40 ligation plus CTLA-4 blockade: more than sum of its parts Oncoimmunology 3 2014 e28245
113. W.L. Redmond, S.N. Linch, and M.J. Kasiewicz Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity Cancer Immunol Res 2 2 2014 142 153
114. E.L. Williams, S.N. Dunn, S. James, and et al. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunorapy in an aggressive murine neuroblastoma model Clin Cancer Res 19 13 2013 3545 3555
115. S.K. Pruitt, D. Boczkowski, N. de Rosa, and et al. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells Eur J Immunol 41 12 2011 3553 3563
116. P.A. Ascierto, M. Kalos, D.A. Schaer, M.K. Callahan, and J.D. Wolchok Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and or tumor types Clin Cancer Res 19 5 2013 1009 1020
117. I. Melero, A.M. Grimaldi, J.L. Perez-Gracia, and P.A. Ascierto Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination Clin Cancer Res 19 5 2013 997 1008
118. I. Melero, I. Martinez-Forero, J. Dubrot, N. Suarez, A. Palazon, and L. Chen Palettes of vaccines and immunostimulatory monoclonal antibodies for combination Clin Cancer Res 15 5 2009 1507 1509
119. F.S. Hodi, S. Lee, D.F. McDermott, and et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial JAMA 312 17 2014 1744 1753
120. A. Korman, B. Chen, C. Wang, L. Wu, P. Cardarelli, and M. Selby Activity of anti-PD-1 in murine tumor models: role of "host" PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4 J Immunol 178 2007 S82 (Meeting Abstract Supplement)
121. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 9 2010 4275 4280
122. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2 2013 122 133
123. M. Sznol, H.M. Kluger, M.K. Callahan, and et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent rapy in advanced melanoma (MEL) ASCO Meeting Abstracts 32 18-suppl 2014 LBA9003
124. M.K. Callahan, J.D. Wolchok, J.P. Allison, and et al. Immune co-signaling to treat cancer TJ Curiel, Cancer immunorapy: Paradigms, practice and potential 2013 Springer New York 211 280
125. J.D. Wolchok, A. Hoos, S. O'Day, and et al. Guidelines for evaluation of immune rapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 23 2009 7412 7420